Constipation in Medical Technology
Navigation Links
Constipation in Medical Technology
... 419 patients with irritable bowel syndrome with constipation (IBS-C). Previous analyses of these data ... of linaclotide in patients with IBS-C or chronic constipation (CC).
(Logo: ...
About Irritable Bowel Syndrome with constipation (IBS-C)
IBS-C is a chronic functional ...
... study of NKTR-118 in patients with opioid-induced constipation (OIC). NKTR-118, a peripheral opioid antagonist, ... which the patient had to demonstrate significant constipation in the absence of laxatives, to the change in ... abdominal cramping, and gastroesophageal reflux. constipation is the hallmark of this syndrome and is generally ...
... 20%, 29%; anorexia 19%, 27%; headache 19%, 23%; constipation 18%, 22%; with the following important adverse ... <1%, 2%; anorexia 1%, 1%; headache 2%, 4%; constipation 1%, 0%; convulsions 3%, 3%; thrombocytopenia 3%, ... 6%, 42%; headache 6%, 41%; fatigue 4%, 34%; constipation 1%, 33%; convulsions 5%, 23%; with the following ...
... The most common treatment-emergent AEs were constipation (64 percent), fatigue (60 percent) and nausea (52 ... weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including ... 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37% vs 16%), neuralgia (36% vs 1%), leukopenia ...
... nausea (31%), fatigue (28%), headache (31%), constipation (21%), diarrhea (22%) and vomiting (21%). The ... (>10%) were rash (28%), pruritus (20%) and constipation (18%). The most common (>10%) Grade 3/4 ... anemia (33%), pyrexia (32%), vomiting (32%), constipation (31%), dyspnea (27%), diarrhea (24%), weakness ...
... 420 patients with irritable bowel syndrome with constipation (IBS-C). Analysis of the data indicates that ... study showing improvement in abdominal pain and constipation are encouraging," said Douglas Drossman, M.D., ... patients diagnosed with IBS-C. About Chronic constipation (CC) As many as 26 million Americans suffer ...
... 419 patients with irritable bowel syndrome with constipation (IBS-C) in a plenary session at the American ... for its potential to treat IBS-C, chronic constipation (CC), and other gastrointestinal disorders. ... patients diagnosed with IBS-C. About Chronic constipation (CC) As many as 26 million Americans suffer ...
... none of the placebo-treated patients. "Chronic constipation is an uncomfortable condition that can ... with CC and irritable bowel syndrome with constipation (IBS-C). Ironwood and Forest previously announced ... and bloating on a daily basis, and constipation severity and overall relief ...
... overall symptoms of Irritable Bowel Syndrome with constipation (IBS-C). These results were presented at ... mcg dose for the treatment of Chronic Idiopathic constipation in adults. These data were among others presented ... About Irritable Bowel Syndrome with constipation (IBS-C) IBS is a disorder characterized by ...
... nausea and vomiting with short-term use, and constipation with longer, chronic use. Such symptoms can lead ... lower incidence of nausea, vomiting, constipation and composite nausea/vomiting (P<0.001) for all ... While the incidence of nausea, vomiting, constipation and the composite nausea and vomiting were ...
... abdominal cramping, and gastroesophageal reflux. constipation is the hallmark of this syndrome, and is ... opioids are likely to experience significant constipation and other symptoms of OBD. According to ... for moderate-to-severe pain revealed that constipation is one of the most common opioid-related side ...
... treatment being developed to treat opioid-induced constipation (OIC) and other clinical manifestations ... tolerability of NKTR-118 in patients experiencing constipation while receiving opioid therapy. "We are excited ... target peripheral opioid receptors to alleviate constipation associated with opioid therapy, while reducing ...
... dysfunction (OBD), including opioid-induced constipation (OIC). Data from a single-dose, ... abdominal cramping, and gastroesophageal reflux. constipation is the hallmark of this syndrome, and is ... opioids are likely to experience significant constipation and other symptoms of OBD. Currently, there are ...
... approved for the treatment of Chronic Idiopathic constipation in adults as AMITIZA(R) (24 mcg, oral gel ... lubiprostone can help many Americans who have constipation as a result of taking opioid-based drugs for ... conditions inclusive of severe constipation brought about by the use of narcotic medications ...
... fatigue, malaise and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy ... neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37% vs 16%), neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting ...
... rash (33%), pruritus (29%), nausea (31%), fatigue (28%), headache (31%), constipation (21%), diarrhea (22%), and vomiting (21%). The most common ( > 10%) ... adverse reactions ( > 10%) were rash (28%), pruritus (20%), and constipation (18%). The most common ( > 10%) Grade 3/4 adverse reactions were ...
... fatigue, malaise and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy ... neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37% vs 16%), neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting ...
... side effects that occurred greater than placebo (a "sugar" pill) were constipation (11.0% vs. 7.0%), indigestion (8.3% vs. 3.5%), nausea (4.2% vs. 3.9%), ... with type 2 diabetes side effects that occurred greater than placebo were constipation (8.7% vs. 2.0%), inflamed nasal passages and throat (4.1% vs. 3.6%), ...
... compound currently being evaluated for the treatment of IBS-C, chronic constipation (CC), and other gastrointestinal disorders. Linaclotide was designed to ... treat the nine million U.S. patients diagnosed with IBS-C. About Chronic constipation (CC) As many as 26 million Americans suffer from CC. Patients with CC ...
... neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37% vs 16%), neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting ... fatigue, malaise and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy ...
... bromide) for the treatment of opioid-induced side effects, including constipation (subcutaneous and oral formulations) and post-operative ileus (intravenous ... subcutaneous injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, ...
... trial, approximately 33 percent were characterized as D-IBS, 37 percent constipation predominant (C-IBS) and 31 percent alternating between diarrhea and constipation (A-IBS). -- In the overall patient group, patients with at least ...
... rash (33%), pruritus (29%), nausea (31%), fatigue (28%), headache (31%), constipation (21%), diarrhea (22%), and vomiting (21%). The most common ( >10%) Grade ... reported adverse reactions ( >10%) were rash (28%), pruritus (20%), and constipation (18%). The most common ( >10%) Grade 3/4 adverse reactions were ...
... were somnolence (34% vs 9%), dry mouth (19% vs 3%), asthenia (10% vs 4%), constipation (10% vs 5%), abdominal pain (7% vs 3%), postural hypotension (7% vs 2%), ... placebo in clinical trials for schizophrenia were dry mouth (12% vs 1%), constipation (6% vs 5%), dyspepsia (5% vs 2%), sedation (13% vs 7%), somnolence (12% vs ...
... (89 percent), anemia (82 percent), pyrexia (53 percent), fatigue (48 percent), nausea (42 percent), cough (40 percent), petechiae (39 percent), constipation (35 percent), and diarrhea (34 percent). Please visit www.dacogen.com for full prescribing information. About Eisai Corporation of ...
... frequency greater than or equal to 10% among lurasidone subjects) for lurasidone versus placebo were nausea (16% vs. 3%), headache (11.1% vs. 10%), constipation (11.1% vs. 5.6%), vomiting (11.1% vs. 5.6%), dyspepsia (11.1% vs. 3.3%), somnolence (11.1% vs. 3.3%), insomnia (10.0% vs. 3.3%) and sedation (10.0% ...
... 2 clinical studies. Carfilzomib was generally well tolerated. The most common adverse events include fatigue headache, nausea, diarrhea, constipation and anemia. Notably, there were no incidents of Grade 3/4 neuropathy, a common side effect associated with the approved proteasome inhibitor, ...
Ironwood Announces Linaclotide European Licensing Agreement with Almirall
... the treatment of irritable bowel syndrome with constipation (IBS-C) and other gastrointestinal conditions. ... for the treatment of IBS-C and chronic constipation (CC). Linaclotide demonstrated proof of concept ... period. In patients with CC, linaclotide reduced constipation throughout the 4-week treatment period. In both ...... study of NKTR-118 in patients with opioid-induced constipation (OIC). NKTR-118, a peripheral opioid antagonist, ... which the patient had to demonstrate significant constipation in the absence of laxatives, to the change in ... abdominal cramping, and gastroesophageal reflux. constipation is the hallmark of this syndrome and is generally ...
... 20%, 29%; anorexia 19%, 27%; headache 19%, 23%; constipation 18%, 22%; with the following important adverse ... <1%, 2%; anorexia 1%, 1%; headache 2%, 4%; constipation 1%, 0%; convulsions 3%, 3%; thrombocytopenia 3%, ... 6%, 42%; headache 6%, 41%; fatigue 4%, 34%; constipation 1%, 33%; convulsions 5%, 23%; with the following ...
... The most common treatment-emergent AEs were constipation (64 percent), fatigue (60 percent) and nausea (52 ... weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including ... 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37% vs 16%), neuralgia (36% vs 1%), leukopenia ...
... nausea (31%), fatigue (28%), headache (31%), constipation (21%), diarrhea (22%) and vomiting (21%). The ... (>10%) were rash (28%), pruritus (20%) and constipation (18%). The most common (>10%) Grade 3/4 ... anemia (33%), pyrexia (32%), vomiting (32%), constipation (31%), dyspnea (27%), diarrhea (24%), weakness ...
... 420 patients with irritable bowel syndrome with constipation (IBS-C). Analysis of the data indicates that ... study showing improvement in abdominal pain and constipation are encouraging," said Douglas Drossman, M.D., ... patients diagnosed with IBS-C. About Chronic constipation (CC) As many as 26 million Americans suffer ...
Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
... the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC), to invest in a growing pipeline of ... linaclotide reduced abdominal pain and relieved constipation -- the hallmarks of the condition -- throughout ...... 419 patients with irritable bowel syndrome with constipation (IBS-C) in a plenary session at the American ... for its potential to treat IBS-C, chronic constipation (CC), and other gastrointestinal disorders. ... patients diagnosed with IBS-C. About Chronic constipation (CC) As many as 26 million Americans suffer ...
New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
... therapy for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are ... to manage their pain, and experts say that constipation occurs in practically all of them. However, for ... United States for the treatment of opioid-induced constipation in patients with advanced illness who ...... none of the placebo-treated patients. "Chronic constipation is an uncomfortable condition that can ... with CC and irritable bowel syndrome with constipation (IBS-C). Ironwood and Forest previously announced ... and bloating on a daily basis, and constipation severity and overall relief ...
... overall symptoms of Irritable Bowel Syndrome with constipation (IBS-C). These results were presented at ... mcg dose for the treatment of Chronic Idiopathic constipation in adults. These data were among others presented ... About Irritable Bowel Syndrome with constipation (IBS-C) IBS is a disorder characterized by ...
... nausea and vomiting with short-term use, and constipation with longer, chronic use. Such symptoms can lead ... lower incidence of nausea, vomiting, constipation and composite nausea/vomiting (P<0.001) for all ... While the incidence of nausea, vomiting, constipation and the composite nausea and vomiting were ...
... abdominal cramping, and gastroesophageal reflux. constipation is the hallmark of this syndrome, and is ... opioids are likely to experience significant constipation and other symptoms of OBD. According to ... for moderate-to-severe pain revealed that constipation is one of the most common opioid-related side ...
Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
... - Chronic constipation and IBS-C studies each meet primary endpoint - ... effects of linaclotide in patients with chronic constipation (CC), while the second study examined its effects ... and constipation severity and overall relief of constipation on a weekly basis. In addition, the use of rescue ...Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies
... is extremely successful at relieving symptoms of constipation and Irritable Bowel Syndrome. In fact, the ... standard for patients seeking relief for their constipation and IBS symptoms. Dr. Edward Group III, the ... to help millions of people suffering from constipation and IBS symptoms, he added, "The results were ...... treatment being developed to treat opioid-induced constipation (OIC) and other clinical manifestations ... tolerability of NKTR-118 in patients experiencing constipation while receiving opioid therapy. "We are excited ... target peripheral opioid receptors to alleviate constipation associated with opioid therapy, while reducing ...
... dysfunction (OBD), including opioid-induced constipation (OIC). Data from a single-dose, ... abdominal cramping, and gastroesophageal reflux. constipation is the hallmark of this syndrome, and is ... opioids are likely to experience significant constipation and other symptoms of OBD. Currently, there are ...
... approved for the treatment of Chronic Idiopathic constipation in adults as AMITIZA(R) (24 mcg, oral gel ... lubiprostone can help many Americans who have constipation as a result of taking opioid-based drugs for ... conditions inclusive of severe constipation brought about by the use of narcotic medications ...
New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
... include: -- For MDD: Nausea, dry mouth and constipation -- For DPNP: Nausea, somnolence (sleepiness), dizziness and constipation -- For GAD: Nausea, fatigue, dry mouth, somnolence (sleepiness) and constipation This is not a complete list of side effects. ...... fatigue, malaise and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy ... neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37% vs 16%), neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting ...
... rash (33%), pruritus (29%), nausea (31%), fatigue (28%), headache (31%), constipation (21%), diarrhea (22%), and vomiting (21%). The most common ( > 10%) ... adverse reactions ( > 10%) were rash (28%), pruritus (20%), and constipation (18%). The most common ( > 10%) Grade 3/4 adverse reactions were ...
... fatigue, malaise and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy ... neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37% vs 16%), neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting ...
... side effects that occurred greater than placebo (a "sugar" pill) were constipation (11.0% vs. 7.0%), indigestion (8.3% vs. 3.5%), nausea (4.2% vs. 3.9%), ... with type 2 diabetes side effects that occurred greater than placebo were constipation (8.7% vs. 2.0%), inflamed nasal passages and throat (4.1% vs. 3.6%), ...
... compound currently being evaluated for the treatment of IBS-C, chronic constipation (CC), and other gastrointestinal disorders. Linaclotide was designed to ... treat the nine million U.S. patients diagnosed with IBS-C. About Chronic constipation (CC) As many as 26 million Americans suffer from CC. Patients with CC ...
... neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37% vs 16%), neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting ... fatigue, malaise and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy ...
... bromide) for the treatment of opioid-induced side effects, including constipation (subcutaneous and oral formulations) and post-operative ileus (intravenous ... subcutaneous injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, ...
... trial, approximately 33 percent were characterized as D-IBS, 37 percent constipation predominant (C-IBS) and 31 percent alternating between diarrhea and constipation (A-IBS). -- In the overall patient group, patients with at least ...
Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
... The most common adverse reactions related to Aloxi were headache (9%) and constipation (5%). Aloxi is contraindicated in patients known to have hypersensitivity ... pyrexia (53%), fatigue (48%), nausea (42%), cough (40%), petechiae (39%), constipation (35%), and diarrhea (34%). Please visit http://www.mgipharma.com or ...... rash (33%), pruritus (29%), nausea (31%), fatigue (28%), headache (31%), constipation (21%), diarrhea (22%), and vomiting (21%). The most common ( >10%) Grade ... reported adverse reactions ( >10%) were rash (28%), pruritus (20%), and constipation (18%). The most common ( >10%) Grade 3/4 adverse reactions were ...
Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
... for the treatment of opioid-induced side effects, including constipation (oral and subcutaneous formulations) and post-operative ileus (intravenous ... formulation of methylnaltrexone for patients suffering from opioid-induced constipation while receiving palliative care, followed in May 2007 by Wyeth's ...... were somnolence (34% vs 9%), dry mouth (19% vs 3%), asthenia (10% vs 4%), constipation (10% vs 5%), abdominal pain (7% vs 3%), postural hypotension (7% vs 2%), ... placebo in clinical trials for schizophrenia were dry mouth (12% vs 1%), constipation (6% vs 5%), dyspepsia (5% vs 2%), sedation (13% vs 7%), somnolence (12% vs ...
Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting
... nausea (48% vs 40%), diarrhea (46% vs 39%), vomiting (32% vs 22%), constipation (31% vs 31%), mucositis/stomatitis (20% vs 5%), peripheral neuropathy ... events were asthenic conditions (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite ...SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
... were somnolence (34% vs 9%), dry mouth (19% vs 3%), asthenia (10% vs 4%), constipation (10% vs 5%), abdominal pain (7% vs 3%), postural hypotension (7% vs 2%), ... placebo in clinical trials for schizophrenia were dry mouth (12% vs 1%), constipation (6% vs 5%), dyspepsia (5% vs 2%), sedation (13% vs 7%), somnolence (12% vs ...Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
... fatigue (80%); thrombosis/embolism (7%); nausea (84%); vomiting (58%); constipation (44%); anorexia (35%); stomatitis/pharyngitis (28%); diarrhea (26%); ... events (all grades) were fatigue (87%); anorexia (62%); nausea (39%); constipation (30%); vomiting (25%); diarrhea (21%); stomatitis/pharyngitis (20%); ...ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
... (72%/71%), dysphagia (65%/63%), asthenia (56%/49%), nausea (49%/37%), constipation (35%/30%) and vomiting (29%/23%). The most common adverse events seen in ... (55%/29%), abdominal pain (45%/26%), vomiting (41%/25%), fever (34%/27%), constipation (30%/26%), and headache (14%/26%). About ImClone Systems ImClone Systems ...Nektar Therapeutics Reports Second Quarter 2009 Financial Results
... across the blood-brain barrier, an important potential advance for small molecule therapies. The product is being developed to treat opioid-induced constipation (OIC). NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, PEGylated ...... (89 percent), anemia (82 percent), pyrexia (53 percent), fatigue (48 percent), nausea (42 percent), cough (40 percent), petechiae (39 percent), constipation (35 percent), and diarrhea (34 percent). Please visit www.dacogen.com for full prescribing information. About Eisai Corporation of ...
... frequency greater than or equal to 10% among lurasidone subjects) for lurasidone versus placebo were nausea (16% vs. 3%), headache (11.1% vs. 10%), constipation (11.1% vs. 5.6%), vomiting (11.1% vs. 5.6%), dyspepsia (11.1% vs. 3.3%), somnolence (11.1% vs. 3.3%), insomnia (10.0% vs. 3.3%) and sedation (10.0% ...
... 2 clinical studies. Carfilzomib was generally well tolerated. The most common adverse events include fatigue headache, nausea, diarrhea, constipation and anemia. Notably, there were no incidents of Grade 3/4 neuropathy, a common side effect associated with the approved proteasome inhibitor, ...
Other ContentsforebrainforebrainforebrainfossilfossilfossilfossilfossilfrondframeshiftfungifungifungifungifungifungifructosefructosefructosefructosefructosefusionfusionfusionfusionfusionfusionfusionfusionfusionOther TagsAnaerobicAnchorAnneal
(Date:12/3/2009)...of plant and animal species can be likened to empt...net full of potential medicines into the trash, or...gers. , But the decline of species and their hab...arch now suggests it may also put you at greater r...destruction and biodiversity loss,"driven by the r...
(Date:12/3/2009)...s message: , , Preliminary Press Conference T... Academy of Sciences museum, Attention PIOs: Sen...ay dinner registration deadline 10 December, Ne...egistration Form pre-registration deadline THIS MO...tant information regarding visas for international...
(Date:12/3/2009)...N.M. Most scientists believe that staph infection...ach other to emit toxins. The signaling process is...be present to start the process. , But the Jeff ...y first stage of staph infection, when bacteria sw... a single cell and that this individual process ca...
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 1Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 2Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 3Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 4FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 14118 1FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 14118 2FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 14118 3FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 14118 4J D Power and Associates Reports 3A Among Pharmacy Customers Satisfaction is Equally as High for the Privately Insured and for Those With Public Pri 57477 1J D Power and Associates Reports 3A Among Pharmacy Customers Satisfaction is Equally as High for the Privately Insured and for Those With Public Pri 57477 2J D Power and Associates Reports 3A Among Pharmacy Customers Satisfaction is Equally as High for the Privately Insured and for Those With Public Pri 57477 3J D Power and Associates Reports 3A Among Pharmacy Customers Satisfaction is Equally as High for the Privately Insured and for Those With Public Pri 57477 4J D Power and Associates Reports 3A Among Pharmacy Customers Satisfaction is Equally as High for the Privately Insured and for Those With Public Pri 57477 5J D Power and Associates Reports 3A Among Pharmacy Customers Satisfaction is Equally as High for the Privately Insured and for Those With Public Pri 57477 6J D Power and Associates Reports 3A Among Pharmacy Customers Satisfaction is Equally as High for the Privately Insured and for Those With Public Pri 57477 7(Date:12/4/2009)...ase Western Reserve University researchers, from t...iscovered two new metabolic pathways by which prod..., known as 4-hydroxyacids, are metabolized. The pa...omics and mass isotopomer analysis. The findings s...ug of abuse gamma-hydroxybutyrate, also known as "...
(Date:12/4/2009)... Dental tourism is a phenome...or an alternative to the high price of dental work...search for lower priced dental care, people have f...e as a dental tourist destination. , ...g in business for more than 6 years, Mexican Denta...
(Date:12/4/2009)...e a response to pressure from federal regulators t... , FRIDAY, Dec. 4 (HealthDay News) -- The mak...iday presented federal regulators with plans to cu...maceutical companies have been under pressure from...nd a way to stop the hundreds of fatal overdoses t...
(Date:12/4/2009)...earch and surveillance urged for at-risk patient g...) -- Some childhood cancers, particularly Ewing sa...e risk of late recurrence, U.S. researchers have f...,795 five-year survivors of the most common pediat...cer Survivor Study. , The researchers found tha...
(Date:12/4/2009)...times more smoke inhaled through hookah, research ...) -- Water pipes are no safer than cigarettes for ... found that people who smoke tobacco with a water ...ts them at risk for heart disease and nicotine add...d 18 to 50, who smoked tobacco using a water pipe ...
Breaking Medicine News(10 mins):Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Makers of Powerful Painkillers Present Safety Plans 2Health News:Water Pipes No Safer Than Cigarettes 2[0] Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week'[0] Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor [0] Makers of Powerful Painkillers Present Safety Plans [0] Certain Childhood Cancers More Likely to Recur[0] Water Pipes No Safer Than Cigarettes
AnaerobeAnabaenaAnaerobicAnagenesisAnaphaseAndrogensAnchorAneuploidAneuploidyAnlageAngiospermAnimaliaAnnealAnnulus
Other Tagspump 2pump 3pump 4pump 5pump 6sell 2sell 3sell 4sell 5sell 6sell 7sell 8sell 9refuse 2refuse 3refuse 4burning 2burning 3raw 2raw 3mediates 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |